3-12-04

Express Mail Label No.: EV 312717423 US Date of Deposit: March 10, 2004

Attorney Docket No.: 24348-501 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Ben-Sasson, et al.

SERIAL NUMBER:

MAR 1 0 2004

10/665,184

EXAMINER:

Not Yet Assigned

Reg. No. 48, 128

FILING DATE:

September 17, 2003

ART UNIT:

1614

For:

AMINO ACID SEQUENCE CAPABLE OF FACILITATING

PENETRATION ACROSS A BIOLOGICAL BARRIER

Mail Stop IDS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (2 pages), in duplicate;
- 3. Copies of Cited References: A1, B1; C1-32; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24348-501 CIP. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

1

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Date: March 10, 2004

Express Mail Label No.: EV 312717423 US

Dete of Deposit: March 10, 2004 Attorney Docket No.: 24348-501 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Ben-Sasson, et al.

SERIAL NUMBER:

€

10/665,184

EXAMINER:

Not Yet Assigned

FILING DATE:

September 17, 2003

ART UNIT:

1614

For:

AMINO ACID SEQUENCE CAPABLE OF FACILITATING

PENETRATION ACROSS A BIOLOGICAL BARRIER

Mail Stop IDS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Ben-Sasson, et al. 10/665,184

MAR 1 0 2004 Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her on conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24348-501 CIP.

Respectfully submitted,

Leg. No. 48, 128 Kor R. Elrifi, Reg. No. 39,529

Attorney for Applicants MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Date: March 10, 2004

TRA 1885648v1

Express Mail Label: EV 312717423 US Date of Deposit: March 10, 2004

Page 1 of 2 Attorney Docket No.: 24348-501 CIP

ase type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

dified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/665,184		
Filing Date	September 17, 2003		
First Named Inventor	Ben-Sasson		
Group Art Unit	Not Yet Assigned		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	24348-501 CIP		

Exam Initlals	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate
	A1	4,873,316	10/10/89	Meade, et al.	530	412	

	FOREIGN PATENT DOCUMENTS							
Initials No. 1		Foreig Office	n Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Trans Yes	Translation Yes No	
	В1	wo	03/066859 A2	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIV. OF JERUSALEM	08/14/03	Yes		

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	e of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
	C1	Amann, et al., Gene, 69(2):301-315 (1988).				
	C2	Armstrong, W.M., <i>Physiol. Gastrointest. Tract</i> , 2 nd Ed., Johnson, ed., Raven Press, New York, 2:1251-1265 (1987).				
	СЗ	Baldari, et al., EMBO J., 6(1):229-234 (1987).				
	C4	Banerji, et al., Cell, 33:729-740 (1983).				
	C5	Bernkop-Schnurch, et al., J. Control. Release, 52:1-16 (1998).				
	C6	Byrne, et al., Proc. Natl. Acad. Sci. USA, 86:5473-5477 (1989).				
	C7	Calame, et al., Adv. Immunol., 43:235-275 (1988).				
	C8	Camper, et al., Genes Dev., 3(4):537-546 (1989).				
	C9	Edlund, et al., Science, 230:912-916 (1985).				
	C10	Fox, Curr. Opin. Pharmacol., 2:338-344 (2002).				
_	C11	Gottesman, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif., ppg. 119-128 (1990).				
	C12	Gumbiner, Am. J. Physiol., 253(6):C749-C758 (1987).				
	C13	Inoue, et al., Inflamm. Res., 45(7):316-323 (1996).				
	C14	Jackson, L.R., Physiol. Gastrointest. Tract, 2nd Ed., Johnson, ed., Raven Press, New York, 2:1597-				

Express Mail Label: EV 312717423 US

Page 2 of 2

Date of Deposit: March 10, 2004

Attorney Docket No.: 24348-501 CIP

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
		1621 (1987).				
	C15	Kaufman, et al., EMBO J., 6:187-195 (1987).				
	C16	Kessel, et al., Science, 249:374-379 (1990).				
	C17	Kurjan, et al., Cell, 30(3):933-943 (1982).				
	C18	Luckow, et al., Virology, 170(1):31-39 (1989).				
	C19	Madara, J. Clin. Invest., 83(4):1089-1094 (1989).				
	C20	Merrifield, R.B., J. Am. Chem. Soc., 85:2151-2154 (1963)				
	C21	O'Shaughnessy, et al., Euro. J. Pharm., 236(2):319-321 (1993).				
	C22	Pinkert, et al., Genes Dev., 1(3):268-277 (1987).				
	C23	Queen, et al., Cell, 33:741-748 (1983).				
	C24	Schilfgaarde, et al., Infect. Immun., 68(8):4616-4623 (2000).				
·	C25	Schultz, et al., Gene, 54(1):113-123 (1987).				
	C26	Seed B., Nature, 329:840-842 (1987).				
	C27	Smith, et al., Mol. Cell. Biol., 3(12):2156-2165 (1983).				
	C28	Studier, et al., Gene Expression Technology: Methods in Enzymology, Academic Press, San Diego, Calif., 185:60-89 (1990).				
•	C29	Wada, et al., Nucl. Acids Res., 20:2111-2118 (1992).				
	C30	Weintraub, et al., "Anti-sense RNA as a Molecular Tool for Genetic Analysis", Reviews-Trends in Genetics, 1:22-25 (1985).				
	C31	Winoto, et al., EMBO J., 8(3):729-733 (1989).				
	C32	Yowell, et al., Cancer Treat. Rev., 28(Suppl. A):3-6 (2002).				

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ______, filed ______, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.